sTREM-1 in patients with chronic kidney disease on hemodialysis

APMIS

Volumn 123, Issue 11, 2015, Pages 969-974

  Essa, Enas S ^a   Elzorkany, Khaled M A ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Chronic kidney disease; Hemodialysis; sTREM 1

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM1 PROTEIN, HUMAN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATION; LABORATORY TEST; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TURBIDIMETRY; BLOOD; CASE CONTROL STUDY; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; SOLUBILITY; YOUNG ADULT;

ADULT; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HEMOGLOBINS; HUMANS; INFLAMMATION MEDIATORS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84945315263     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12459     Document Type: Article

References (46)

1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
2. Nolan CR. Strategies for improving long-term survival in patients with ESRD. J Am Soc Nephrol 2005;16(Suppl 2):S120-7.
3. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002;15:329-37.
4. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al. IL-10, IL-6, and TNF-α: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005;67:1216-33.
5. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008;3:505-21.
6. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000;164:4991-5.
7. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 2009;21:38-46.
8. Gibot S, Kolopp-Sarda MN, Bene MC, Bollaert PE, Lozniewski A, Mory F, et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 2004;200:1419-26.
9. Gibot S, Le Renard PE, Bollaert PE, Kolopp-Sarda MN, Bene MC, Faure GC, et al. Surface triggering receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med 2005;31:594-7.
10. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001;410:1103-7.
11. Radsak MP, Taube C, Haselmayer P, Tenzer S, Salih HR, Wiewrodt R, et al. Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol 2007;2007:52040.
12. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004;350:451-8.
13. Richeldi L, Mariani M, Losi M, Maselli F, Corbetta L, Buonsanti C, et al. Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections. Eur Respir J 2004;24:247-50.
14. Tejera A, Santolaria F, Diez ML, Aleman-Valls MR, Gonzalez-Reimers E, Martinez-Riera A, et al. Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine 2007;38:117-23.
15. Determann RM, Millo JL, Gibot S, Korevaar JC, Vroom MB, van der Poll T, et al. Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia. Intensive Care Med 2005;31:1495-500.
16. El Solh AA, Akinnusi ME, Peter M, Berim I, Schultz MJ, Pineda L. Triggering receptors expressed on myeloid cells in pulmonary aspiration syndromes. Intensive Care Med 2008;34:1012-9.
17. Chan MC, Chang KM, Chao WC, Lin LY, Kuo BI, Hsu JY, et al. Evaluation of a new inflammatory molecule (triggering receptor expressed on myeloid cells-1) in the diagnosis of pleural effusion. Respirology 2007;12:333-8.
18. Liu CL, Hsieh WY, Wu CL, Kuo HT, Lu YT. Triggering receptor expressed on myeloid cells-1 in pleural effusions: a marker of inflammatory disease. Respir Med 2007;101:903-9.
19. Yasuda T, Takeyama Y, Ueda T, Shinzeki M, Sawa H, Takahiro N, et al. Increased levels of soluble triggering receptor expressed on myeloid cells-1 in patients with acute pancreatitis. Crit Care Med 2008;36:2048-53.
20. Wang DY, Qin RY, Liu ZR, Gupta MK, Chang Q. Expression of TREM-1 mRNA in acute pancreatitis. World J Gastroenterol 2004;10:2744-6.
21. Koussoulas V, Vassiliou S, Demonakou M, Tassias G, Giamarellos-Bourboulis EJ, Mouktaroudi M, et al. Soluble triggering receptor expressed on myeloid cells (sTREM-1): a new mediator involved in the pathogenesis of peptic ulcer disease. Eur J Gastroenterol Hepatol 2006;18:375-9.
22. Tzivras M, Koussoulas V, Giamarellos-Bourboulis EJ, Tzivras D, Tsaganos T, Koutoukas P, et al. Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease. World J Gastroenterol 2006;12:3416-9.
23. Schenk M, Bouchon A, Seibold F, Mueller C. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest 2007;117:3106.
24. Park JJ, Cheon JH, Kim BY, Kim DH, Kim ES, Kim TI, et al. Correlation of serum- soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Dig Dis Sci 2009;54:1525-31.
25. Knapp S, Gibot S, de Vos A, Versteeg HH, Colonna M, van der Poll T. Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. J Immunol 2004;173:7131-4.
26. How CK, Chern CH, Wu MF, Wang LM, Huang CI, Lee CH, et al. Expression of the triggering receptor expressed on myeloid cells-1 mRNA in a heterogeneous infected population. Int J Clin Pract 2007.
27. Murakami Y, Akahoshi T, Hayashi I, Endo H, Kawai S, Inoue M, et al. Induction of triggering receptor expressed on myeloid cells 1 in murine resident peritoneal macrophages by monosodium urate monohydrate crystals. Arthritis Rheum 2006;54:455-62.
28. Ho CC, Liao WY, Wang CY, Lu YH, Huang HY, Chen HY, et al. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med 2008;177:763-70.
29. Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, Marzano L, et al. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis 2002;39:266-73.
30. Hung A, Pupim L, Yu C, Shintani A, Siew E, Ayus C, et al. Determinants of C-reactive protein in chronic hemodialysis patients: relevance of dialysis catheter utilization. Hemodial Int 2008;12:236-43.
31. Ren H, Zhou X, Luan Z, Luo X, Han S, Cai Q, et al. The relationship between carotid atherosclerosis, inflammatory cytokines, and oxidative stress in middle aged and elderly hemodialysis patients. Int J Nephrol 2013;2013:835465.
32. Tbahriti HF, Meknassi D, Moussaoui R, Messaoudi A, Zemour L, Kaddous A, et al. Inflammatory status in chronic renal failure: the role of homocysteinemia and pro-inflammatory cytokines. World J Nephrol 2013;2:31-7.
33. Babaei M, Dashti N, Lamei N, Abdi K, Nazari F, Abbasian S, et al. Evaluation of plasma concentrations of homocysteine, IL-6, TNF-alpha, hs-CRP, and total antioxidant capacity in patients with end-stage renal failure. Acta Med Iran 2014;52:893-8.
34. Tammaro A, Stroo I, Rampanelli E, Blank F, Butter LM, Claessen N, et al. Role of TREM1-DAP12 in renal inflammation during obstructive nephropathy. PLoS ONE 2013;8:e82498.
35. Campanholle G, Mittelsteadt K, Nakagawa S, Kobayashi A, Lin SL, Gharib SA, et al. TLR-2/TLR-4 TREM-1 signaling pathway is dispensable in inflammatory myeloid cells during sterile kidney injury. PLoS ONE 2013;8:e68640.
36. Gibot S, Alauzet C, Massin F, Sennoune N, Faure GC, Béné MC, et al. Modulation of the triggering receptor expressed on myeloid cells-1 pathway during pneumonia in rats. J Infect Dis 2006;194:975-83.
37. Gibot S, Massin F, Marcou M, Taylor V, Stidwill R, Wilson P, et al. TREM-1 promotes survival during septic shock in mice. Eur J Immunol 2007;37:456-66.
38. Sharif O, Knapp S. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 2008;213:701-13.
39. Bleharski JR, Kiessler V, Buonsanti C, Sieling PA, Stenger S, Colonna M, et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early induced and adaptive phases of the immune response. J Immunol 2003;170:3812-8.
40. Netea MG, Azam T, Ferwerda G, Girardin SE, Kim SH, Kim SH, et al. Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition receptors. J Leukoc Biol 2006;80:1454-61.
41. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006;7:1266-73.
42. Derive M, Massin F, Gibot S. Triggering receptor expressed on myeloid cells-1 as a new therapeutic target during inflammatory diseases. Self Nonself 2010;1:225-30.
43. Chawla LS, Krishnan M. Causes and consequences of inflammation on anemia management in haemodialysis patients. Hemodial Int 2009;13:222-34.
44. Allen DA, Breen C, Yaqoob MM, Macdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and IL-1. J Invest Med 1999;47:204-11.
45. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beerman NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 1998;13:82-8.
46. Eleftheriadis T, Liaopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial 2009;22:70-7.